Artwork

Innhold levert av Dementia Researcher. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Dementia Researcher eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
Player FM - Podcast-app
Gå frakoblet med Player FM -appen!

A Closer Look At Lecanemab Donanemab And Amyloid

54:21
 
Del
 

Manage episode 383216087 series 2114488
Innhold levert av Dementia Researcher. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Dementia Researcher eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.
  continue reading

266 episoder

Artwork
iconDel
 
Manage episode 383216087 series 2114488
Innhold levert av Dementia Researcher. Alt podcastinnhold, inkludert episoder, grafikk og podcastbeskrivelser, lastes opp og leveres direkte av Dementia Researcher eller deres podcastplattformpartner. Hvis du tror at noen bruker det opphavsrettsbeskyttede verket ditt uten din tillatelse, kan du følge prosessen skissert her https://no.player.fm/legal.
In this podcast Dr Anna Volkmer, convenes a panel of world-renowned experts from University College London. They discuss the discovery of amyloid and its role in Alzheimer’s Disease and take an in-depth look into the latest developments surrounding Lecanemab and Donanemab, monoclonal antibodies (mAbs) as a treatment and Gene Silencing. This week’s guests are Professor Sir John Hardy, Geneticist and trailblazer in neurodegenerative disease research, Professor Nick Fox, Neurologist, and eminent figure in the fields of neuroimaging and clinical neuroscience, and Dr Cath Mummery, Neurologist and leading light in cognitive disorders and clinical trials. -- Listeners can expect: 1. 🧠 - Discussion on new dementia drugs Lecanemab and Donanemab. 2. 🔬 - Insights on the science behind these treatments, the story behind the discovery of amyloid and familial Alzheimer’s - Carol Jennings Story. 3. ❌🤔 - Clarification of misconceptions about dementia therapies. 4. 🩺💊 - Information on the impact of these drugs on patients and clinical practice. 5. 🌟🔜 - A look at the future of dementia research, including gene-silencing therapies. -- NIA statement on report of lecanemab reducing cognitive decline in Alzheimer’s clinical trial: https://www.nia.nih.gov/news/nia-statement-report-lecanemab-reducing-cognitive-decline-alzheimers-clinical-trial NIA statement on donanemab results: More Alzheimer’s research progress: https://www.nia.nih.gov/news/nia-statement-donanemab-results-more-alzheimers-research-progress Alzheimer's Society Information on Donanemab: https://www.alzheimers.org.uk/blog/what-is-donanemab-alzheimers-drug Alzheimer's Society Information on Lebanemab: https://www.alzheimers.org.uk/blog/lecanemab-new-drug-early-stage-alzheimers-disease Alzheimer's Association Info on Research & Risks https://bit.ly/3QxH3Ei -- Full biographies on all our guests and a transcript can be found on our website http://www.dementiaresearcher.nihr.ac.uk -- Like what you hear? Please review, like, and share our podcast - and don't forget to subscribe to ensure you never miss an episode – and if you prefer to watch rather than listen, you’ll find a video version of this podcast with full captions on our YouTube Channel. https://youtu.be/Kl8rzDSIwxM -- This podcast is brought to you by University College London / UCLH NIHR Biomedical Research Centre in association with Alzheimer’s Association, Alzheimer's Research UK, Alzheimer's Society and Race Against Dementia who we thank for their ongoing support.
  continue reading

266 episoder

Alle episoder

×
 
Loading …

Velkommen til Player FM!

Player FM scanner netter for høykvalitets podcaster som du kan nyte nå. Det er den beste podcastappen og fungerer på Android, iPhone og internett. Registrer deg for å synkronisere abonnement på flere enheter.

 

Hurtigreferanseguide

Copyright 2024 | Sitemap | Personvern | Vilkår for bruk | | opphavsrett